133 related articles for article (PubMed ID: 38151760)
1. Elucidating the glucose-lowering effect of the bile acid sequestrant sevelamer.
Nerild HH; Brønden A; Haddouchi AE; Ellegaard AM; Hartmann B; Rehfeld JF; Holst JJ; Sonne DP; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2024 Apr; 26(4):1252-1263. PubMed ID: 38151760
[TBL] [Abstract][Full Text] [Related]
2. The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes.
Brønden A; Albér A; Rohde U; Gasbjerg LS; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2018 Feb; 20(2):362-369. PubMed ID: 28786523
[TBL] [Abstract][Full Text] [Related]
3. Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study.
Xie C; Iroga P; Bound MJ; Grivell J; Huang W; Jones KL; Horowitz M; Rayner CK; Wu T
Diabetologia; 2024 Jul; 67(7):1260-1270. PubMed ID: 38561463
[TBL] [Abstract][Full Text] [Related]
4. The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes.
Dalsgaard NB; Gasbjerg LS; Hansen LS; Hansen NL; Stensen S; Hartmann B; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Eur J Endocrinol; 2021 Mar; 184(3):383-394. PubMed ID: 33449919
[TBL] [Abstract][Full Text] [Related]
5. Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer.
Brønden A; Mikkelsen K; Sonne DP; Hansen M; Våben C; Gabe MN; Rosenkilde M; Tremaroli V; Wu H; Bäckhed F; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2018 Jul; 20(7):1623-1631. PubMed ID: 29493868
[TBL] [Abstract][Full Text] [Related]
6. Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes.
Dalsgaard NB; Gasbjerg LS; Helsted MM; Hansen LS; Hansen NL; Skov-Jeppesen K; Hartmann B; Holst JJ; Vilsbøll T; Knop FK
Bone; 2023 May; 170():116687. PubMed ID: 36754130
[TBL] [Abstract][Full Text] [Related]
7. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.
Beysen C; Murphy EJ; Deines K; Chan M; Tsang E; Glass A; Turner SM; Protasio J; Riiff T; Hellerstein MK
Diabetologia; 2012 Feb; 55(2):432-42. PubMed ID: 22134839
[TBL] [Abstract][Full Text] [Related]
8. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
[TBL] [Abstract][Full Text] [Related]
9. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
[TBL] [Abstract][Full Text] [Related]
10. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
[TBL] [Abstract][Full Text] [Related]
11. Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes.
Brønden A; Albér A; Rohde U; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2017 Nov; 102(11):4153-4162. PubMed ID: 28938439
[TBL] [Abstract][Full Text] [Related]
12. Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in β-Cell Function in Patients With Type 2 Diabetes.
Stensen S; Gasbjerg LS; Rosenkilde MM; Vilsbøll T; Holst JJ; Hartmann B; Christensen MB; Knop FK
Diabetes; 2022 Oct; 71(10):2209-2221. PubMed ID: 35796651
[TBL] [Abstract][Full Text] [Related]
13. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.
Bahne E; Sun EWL; Young RL; Hansen M; Sonne DP; Hansen JS; Rohde U; Liou AP; Jackson ML; de Fontgalland D; Rabbitt P; Hollington P; Sposato L; Due S; Wattchow DA; Rehfeld JF; Holst JJ; Keating DJ; Vilsbøll T; Knop FK
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518693
[TBL] [Abstract][Full Text] [Related]
14. Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass.
Jonsson I; Bojsen-Møller KN; Kristiansen VB; Veedfald S; Wewer Albrechtsen NJ; Clausen TR; Kuhre RE; Rehfeld JF; Holst JJ; Madsbad S; Svane MS
Front Endocrinol (Lausanne); 2021; 12():681116. PubMed ID: 34084153
[TBL] [Abstract][Full Text] [Related]
15. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
17. Exendin(9-39)NH
Gasbjerg LS; Bari EJ; Christensen M; Knop FK
Diabetes Obes Metab; 2021 Nov; 23(11):2419-2436. PubMed ID: 34351033
[TBL] [Abstract][Full Text] [Related]
18. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes.
Smushkin G; Sathananthan M; Piccinini F; Dalla Man C; Law JH; Cobelli C; Zinsmeister AR; Rizza RA; Vella A
Diabetes; 2013 Apr; 62(4):1094-101. PubMed ID: 23250357
[TBL] [Abstract][Full Text] [Related]
19. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.
Hansen M; Scheltema MJ; Sonne DP; Hansen JS; Sperling M; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2016 Jun; 18(6):571-80. PubMed ID: 26888164
[TBL] [Abstract][Full Text] [Related]
20. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
